VJHemOnc is committed to improving our service to you

ESH AL 2020 | Molecular profiling to determine treatment for ALL and AML

VJHemOnc is committed to improving our service to you

Oliver Ottmann

Oliver Ottmann, MD, FRCPath, University of Cardiff, Cardiff, UK, discusses how molecular profiling and genome sequencing will act as a turning point for deciding treatment options for patients with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). This is due to prevalent genetic aberrations in these diseases. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJhemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter